CLINICAL_TRIALS
trial_result
· 2022-12-15
Clinical Trial Update: An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis [Phase 3]
Summary
Phase 3 study evaluating the efficacy and safety of apremilast in adults with moderate to severe genital psoriasis has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2022-12-15